Alimera Sciences Stock News

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d

10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M

The Opthea Ltd (ASX: OPT) share price has been a standout performer in the mid-cap ASX healthcare sector, up more than 350% in the past 12 months.

Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema

10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M

Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that the first patients have been enrolled in a multinational, prospective, o

Regulatory News: The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division

$7.6 billion deal announced in August 2019; expected to be completed by mid-year 2020.

The European Commission has granted approval to Elanco Animal Health's pending acquisition of Bayer's animal health business.

We are getting close to crunch point in the Brexit negotiations.  Last week saw the culmination of the final round

As the number of fatalities due to COVID-19 in Telangana stands at 113 as of June 5, with the 100-figure mark having breached the previous day, it is interesting to note that 79 of these deaths were r

04.06.2020

Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that its indepen